Ondine Biomedical, a leading Canadian biotech entity, is making significant strides in the development of innovative light-activated antimicrobial treatments. According to an independent study conducted at the globally recognized Mazankowski Alberta Heart Institute, the application of Ondine’s Steriwave as a replacement for the conventional antibiotic, Mupirocin, led to a substantial reduction of cardiac surgical site infections (SSIs) by 32%. This groundbreaking development was recently detailed in a poster presentation at the prominent AMMI Canada-CACMID annual conference on clinical microbiology and infectious diseases.
The pilot implementation of Steriwave, in replacement of Mupirocin—an antibiotic with alarmingly high resistance rates, was undertaken in June 2023. Surgical site infection rates plummeted from an average of 1.67 per 100 surgeries before the introduction of this groundbreaking therapy to 0.7 per 100 surgeries after its implementation. The financial implication of this considerable reduction in SSIs is considerable, with estimates pointing to savings amounting to $56,000 in the Q4 alone. Steriwave’s application saw a 94% compliance rate, with no reported adverse reactions, marking additional victories in the ongoing battle against SSIs. SSIs are particularly serious complications often associated with cardiac surgery interventions.
They are responsible for a considerable increase in patient recovery time, medication costs, and overall healthcare expenditure. Steriwave’s unique light-activated antimicrobial mechanism destroys a variety of pathogens, including bacteria, fungi, and viruses, making it a formidable ally against SSIs. It is immediately effective after a single five-minute treatment and doesn’t contribute to antimicrobial resistance (AMR), unlike traditional antibiotics. The heartening initial results from the implementation of Steriwave at the Mazankowski Alberta Heart Institute underpin the urgent need to explore alternatives to antibiotics amid mounting concerns over antibiotic resistance and compliance challenges. The encouraging results from Steriwave’s application are particularly significant considering the growing global concern over the dramatic rise of antibiotic-resistant pathogens. In conclusion, Ondine’s Steriwave has shown promising signs as the much-needed next step in infection prevention in surgical settings, offering a highly effective and well-tolerated method that combines patient compliance with significant cost reductions.